Despite a decade’s worth of turbulence for the market, much of it painful, it’s amazing how so many investors keep coming back to the same stocks and the same stories that have already punished their portfolios at least once. Examples of these let-downs include… Read More

For the millions of Americans who suffer from high cholesterol, Nov. 30 will be a big day. That’s when Pfizer’s (NYSE: PFE) blockbuster drug Lipitor will lose patent protection, promising massive savings for high-cholesterol patients. The $7 billion drug (according to projected 2011 sales) also represents a big deal for… Read More

You hear it all the time. Save for retirement! Many financial experts — including my favorite, Suze Orman — tell you to contribute to a Roth IRA or traditional IRA outside of your… Read More

In just a matter of days, the third quarter will finally come to an end, and barring an end-of-the month rally, investors will be tallying up the losses. As it currently stands, the S&P 500 is on track for a 15% loss, erasing all of the gains of the previous… Read More

If you’ve visited the grocery store lately, then you’ve probably noticed prices for basic food items such as bread and ground beef have soared this year. The increase is mainly as result of skyrocketing prices for commodities. Wheat prices, for instance, have climbed 65% just in the past year, while… Read More

The market has surged and plunged during the past two years, but two things have remained constant. Companies continue to generate lots of cash. And lacking any real options to re-invest that cash back into their business, they’re hiking or initiating new dividends at a rapid rate. Read More

We are on the brink of a revolution. But let me tell you, this revolution doesn’t involve explosive growth in Asia, the collapse of the euro, or the end of the world as we know it (although some may be wondering about that in light of today’s… Read More

On Tuesday, I brought my Scarcity & Real Wealth subscribers some important news, some of it bad, some of it good. The bad news: rare earth miner Molycorp (NYSE: MCP), one of my favorite stocks in this exciting sector, was down 22% on Tuesday, Sept. 20. Since then, it’s fallen… Read More

In recent weeks, I’ve been focusing all my efforts on large- and mid-cap stocks, especially those with strong balance sheets and consistent free cash flow. Many of these rock-solid companies offer a degree of stability in this… Read More